[Efficacy and safety of the new generation of excimer laser trabeculotomy in a heterogeneous patient population-1-year follow-up].

Stefanie Gniesmer, Svenja Rebecca Sonntag, Swaantje Grisanti
{"title":"[Efficacy and safety of the new generation of excimer laser trabeculotomy in a heterogeneous patient population-1-year follow-up].","authors":"Stefanie Gniesmer, Svenja Rebecca Sonntag, Swaantje Grisanti","doi":"10.1007/s00347-024-02126-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Microinvasive procedures have become established in glaucoma surgery and are preferred for patients with target pressure values that are not too low. Excimer laser trabeculotomy (ELT) represents such a minimally invasive approach and can easily be combined with cataract surgery.</p><p><strong>Objective: </strong>Over 12 months the reduction in intraocular pressure (IOP), the number of antiglaucoma drugs and the incidence of adverse events were evaluated using the new Elios<sup>TM</sup> method (Elios Vision GmbH, Germering, Germany) for real-life data from a heterogeneous patient population undergoing ELT in combination with cataract surgery (phaco-ELT).</p><p><strong>Material and methods: </strong>In this study 20 eyes of 13 patients who underwent phaco-ELT were retrospectively analyzed. After standard phacoemulsification with posterior chamber lens implantation, 10 microchannels were created using the excimer laser. The patients were followed for 12 months and the intraocular pressure (IOP), number of antiglaucoma drugs and the occurrence of adverse events were analyzed.</p><p><strong>Results: </strong>The average age was 65 years. The preoperative IOP was 17.5 (± 5.3) mm Hg. The mean IOP reduction was 4.8 mm Hg (27.4%, p < 0.001) on the first postoperative day, 3.2 mm Hg (18.3%, p = 0.22) after 6 months and 2.5 mm Hg (14.3%, p = 0.14) at 12 months. The number of antiglaucoma drugs decreased from an average of 3.2 (± 1.3) preoperatively to 0.5 (± 0.9) on day 1 (p < 0.001), 1.9 (± 1.2) after 6 months (p = 0.008) and 2.2 (± 1.3) after 12 months (p = 0.013).</p><p><strong>Discussion: </strong>In our cohort ELT in combination with cataract surgery is a safe minimally invasive procedure leading to an IOP reduction of 14.3% and a reduction of pressure-lowering medication by 1 active ingredient in patients with low initial pressure at 1‑year follow-up. As no implant is used in ELT and the conjunctiva remains untouched, subsequent procedures, including bleb-related surgery, are not negatively affected.</p>","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Die Ophthalmologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s00347-024-02126-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Microinvasive procedures have become established in glaucoma surgery and are preferred for patients with target pressure values that are not too low. Excimer laser trabeculotomy (ELT) represents such a minimally invasive approach and can easily be combined with cataract surgery.

Objective: Over 12 months the reduction in intraocular pressure (IOP), the number of antiglaucoma drugs and the incidence of adverse events were evaluated using the new EliosTM method (Elios Vision GmbH, Germering, Germany) for real-life data from a heterogeneous patient population undergoing ELT in combination with cataract surgery (phaco-ELT).

Material and methods: In this study 20 eyes of 13 patients who underwent phaco-ELT were retrospectively analyzed. After standard phacoemulsification with posterior chamber lens implantation, 10 microchannels were created using the excimer laser. The patients were followed for 12 months and the intraocular pressure (IOP), number of antiglaucoma drugs and the occurrence of adverse events were analyzed.

Results: The average age was 65 years. The preoperative IOP was 17.5 (± 5.3) mm Hg. The mean IOP reduction was 4.8 mm Hg (27.4%, p < 0.001) on the first postoperative day, 3.2 mm Hg (18.3%, p = 0.22) after 6 months and 2.5 mm Hg (14.3%, p = 0.14) at 12 months. The number of antiglaucoma drugs decreased from an average of 3.2 (± 1.3) preoperatively to 0.5 (± 0.9) on day 1 (p < 0.001), 1.9 (± 1.2) after 6 months (p = 0.008) and 2.2 (± 1.3) after 12 months (p = 0.013).

Discussion: In our cohort ELT in combination with cataract surgery is a safe minimally invasive procedure leading to an IOP reduction of 14.3% and a reduction of pressure-lowering medication by 1 active ingredient in patients with low initial pressure at 1‑year follow-up. As no implant is used in ELT and the conjunctiva remains untouched, subsequent procedures, including bleb-related surgery, are not negatively affected.

[新一代准分子激光小梁切开术在异质患者群体中的疗效和安全性--1 年随访]。
背景:微创手术已在青光眼手术中得到确立,对于目标眼压值不是太低的患者来说,微创手术是首选。准分子激光小梁切开术(ELT)就是这种微创方法的代表,而且很容易与白内障手术结合使用:目的:使用新的 EliosTM 方法(Elios Vision GmbH, Germering, Germany)评估了 12 个月内眼压(IOP)的降低情况、抗青光眼药物的使用次数以及不良事件的发生率,这些数据来自接受准分子激光小梁切开术与白内障手术(phaco-ELT)联合治疗的异质性患者群体的真实数据:本研究对 13 名接受超声乳化联合白内障手术的患者的 20 只眼睛进行了回顾性分析。在标准乳化术和后房人工晶体植入术后,使用准分子激光创建了 10 个微通道。对患者进行了为期12个月的随访,分析了眼压、抗青光眼药物的使用次数以及不良反应的发生情况:结果:患者平均年龄为 65 岁。结果:患者平均年龄 65 岁,术前眼压为 17.5 (± 5.3) mm Hg。平均眼压降低了 4.8 毫米汞柱(27.4%,P 讨论):在我们的队列中,ELT 与白内障手术相结合是一种安全的微创手术,可使眼压降低 14.3%,在随访 1 年时,初始眼压较低的患者可减少 1 种有效成分的降压药物。由于 ELT 没有使用植入物,结膜也未受到影响,因此不会对后续手术(包括眼泡相关手术)产生负面影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信